Spots Global Cancer Trial Database for This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.
Official Title: Oral ST1481 in Adults With Malignant Glioma: a Phase I-II Clinical Trial
Study ID: NCT00032903
Conditions
Interventions
Study Description
Brief Summary: Gimatecan® is Sigma-Tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determine the Maximum Tolerated Dose of our compound. In addition, we plan to assess the drug's ability to affect the evolution of malignant gliomas, when given as a capsule, rather than by intravenous injection.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Rhode Island Hospital, Providence, Rhode Island, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
